Endometrial adenocarcinoma is the most common malignancy of the female genital tract, and occurs at elevated frequency in women who have premalignant endometrial lesions or are exposed to estrogens for protracted intervals. Somatically acquired loss of function of the PTEN tumor suppressor gene is an initiating event in sporadic endometrial carcinogenesis, which characterizes two thirds of histologically evident precancers (EIN, or atypical endometrial hyperplasia) and their resultant endometrial cancers. Small numbers of PTEN-null histologically unremarkable endometrial glands, """"""""latent precancers"""""""" can be found in the endometrium of almost half of normal women, indicating that progression efficiency rather than initiation, is the major barrier to carcinogenesis. We postulate that hormonal factors which modulate endometrial cancer risk act to cause expansion/persistence or involution/disappearance of pre-existing somatically acquired mutant endometrial clones. We will test this hypothesis by tracking the fate of PTEN-null endometrial clones in sequential biopsies of women undergoing hormonal replacement therapy known to increase (unopposed estrogen) or decrease (combined estrogen and progestin) risk of endometrial adenocarcinoma. Changing trends in the fraction of women with PTEN-null endometrial clones will be measured as a function of hormonal exposure type and duration (SA#1). In SA#2, specific PTEN mutations will be used as clonal markers to distinguish between persistence of individual clones over time and successive initiation of multiple short lived clones. SA#3 will correlate endometrial histopathology with clonal progression from a histologically latent to diagnosable stage. If our hypothesis is confirmed, this project will establish biomarker-detectable preclinical disease as a surrogate marker for risk surveillance, and a potential target for cancer preventative therapies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA100833-01A1
Application #
6770880
Study Section
Special Emphasis Panel (ZRG1-CBSS (01))
Program Officer
Wang, Wendy
Project Start
2004-06-01
Project End
2009-05-31
Budget Start
2004-06-01
Budget End
2005-05-31
Support Year
1
Fiscal Year
2004
Total Cost
$272,475
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Mutter, George L; Monte, Nicolas M; Neuberg, Donna et al. (2014) Emergence, involution, and progression to carcinoma of mutant clones in normal endometrial tissues. Cancer Res 74:2796-802
Quick, Charles M; Laury, Anna R; Monte, Nicolas M et al. (2012) Utility of PAX2 as a marker for diagnosis of endometrial intraepithelial neoplasia. Am J Clin Pathol 138:678-84
Semere, Luwam G; Ko, Emily; Johnson, Natasha R et al. (2011) Endometrial intraepithelial neoplasia: clinical correlates and outcomes. Obstet Gynecol 118:21-8
Monte, Nicolas M; Webster, Kaitlyn A; Neuberg, Donna et al. (2010) Joint loss of PAX2 and PTEN expression in endometrial precancers and cancer. Cancer Res 70:6225-32
Lin, Ming-Chieh; Lomo, Lesley; Baak, Jan P A et al. (2009) Squamous morules are functionally inert elements of premalignant endometrial neoplasia. Mod Pathol 22:167-74
Lin, Ming-Chieh; Burkholder, Kyla A; Viswanathan, Akila N et al. (2009) Involution of latent endometrial precancers by hormonal and nonhormonal mechanisms. Cancer 115:2111-8
Carlson, J W; Mutter, G L (2008) Endometrial intraepithelial neoplasia is associated with polyps and frequently has metaplastic change. Histopathology 53:325-32